WALTHAM, Mass., May 16, 2019 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that i
Source: www.prnewswire.com
Thermo Fisher Scientific Inc. has finalized an agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline for ~€90 million in an all-cash transaction. The acquired site in Cork will expand Thermo Fishers’ capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). The Company will also continue to produce APIs for GSK under a multi-year supply agreement. The transaction is expected to close by the end of 2019.
